Cost-effectiveness analysis of the bevacizumab-irinotecan regimen in the treatment of primary glioblastoma multiforme recurrences

The purpose of the present study was to calculate the cost-effectiveness of the inclusion of the bevacizumab (BVZ) + irinotecan (CPT-11) regimen in the second-line of treatment for primary glioblastoma multiforme. A retrospective cohort study with a control group was performed in which the cost-effe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncol Lett
Main Authors: Ruiz-Sánchez, Daniel, Peinado, Irene Iglesias, Alaguero-Calero, Miguel, Sastre-Heres, Alejandro José, Diez, Benito García, Peña-Díaz, Jaime
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2016
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4998143/
https://ncbi.nlm.nih.gov/pubmed/27588142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2016.4871
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados